WAT logo

WATERS CORP

WATNYSE
πŸ† #341 by market capEarnings Nov 2 Β· PreUS Equity
$441.09β–Ό $1.85 (βˆ’0.42%)
Live
πŸ””
Track WAT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.4%
7dβ–² 3.6%
14dβ–² 5.8%
30dβ–² 6.4%
ytdβ–² 16.0%
1yβ–² 52.6%
🏦Market Cap
$43.31B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+7.0%
Slowing
πŸ“ŠGross Margin
50.8%
Healthy
πŸ’΅FCF Margin
8.6%
Moderate
βš–οΈP/S Ratio
9.2x
Elevated
Otter Score
64
Fair

Trading Snapshot

Day Range
$439.64 – $446.52
52-Week Range
$282.77 – $436.34
Volume
$5.68B
Avg Volume
$6.25B
Shares Outstanding
98.2M
Next Earnings
Dec 4, 2026

Fundamentals Snapshot

Annual Revenue
$3.17B
Last Q Revenue
$1.65B
P/E Ratio
107.8
P/S Ratio
9.2x
EPS (TTM)
$1.69
Dividend Yield
0.00%
Dilution (1yr)
+0.2%

Why Investors Own WAT

  • βœ“High-growth profile β€” revenue up +21.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 39% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

WAT logo

WATERS CORP

WAT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3.2Bβ–² +7.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
57.8%β–Ό βˆ’2.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$893Mβ–² +8.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$540Mβ–Ό βˆ’12.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
59.8Mβ–² +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$903Mβ–² +$475M YoY
StockOtter Β· stockotter.space

About WATERS CORP

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Buy
31 analysts
Strong Buy9
Buy11
Hold11
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

MarketBeatΒ·3d ago

Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum

Waters NYSE: WAT President and Chief Executive Officer Udit Batra said the company's second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early

Seeking AlphaΒ·6d ago

Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript

Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript

Zacks Investment ResearchΒ·7d ago

Still Waters Bring Mixed Pre-Market Levels

A grand total of zero monthly or quarterly economic reports have come out so far this week.

Zacks Investment ResearchΒ·11d ago

Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry

WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.

Business WireΒ·13d ago

Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients

AUSTIN, Texas--(BUSINESS WIRE)--Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervical cancer screening

PRNewsWireΒ·15d ago

Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer

Enables routine 50+ parameter experiments with BD SpectralFXβ„’ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. Minimizes instrument and user differences with first-of-its-